Update on HER-2 directed therapy
Treatment guidelines for systemic adjuvant therapy of breast cancer: strengths and weaknesses
Emerging ethical issues in cancer genetic testing
In situ proteomics in cancer tissues using mass spectrometry
Identification and testing of a gene expression signature for invasion and metastasis in mammary tumors
Tomosynthesis: a new tool for breast cancer detection
New carbon nanostructures for imaging and therapy of breast cancer
Gold nanoshells as a new treatment strategy for breast Cancer
Nanotechnology in terms of biomedical applications in cancer and opportunities for funding
Detection of circulating breast cancer cells: are these the cells that really matter?
Identification and testing of a gene expression signature for invasion and metastasis in mammary tumors
Breast cancer metastasis genes and functions
Developmental and therapeutic implications of molecular profiles of ER-positive and ER-negative breast cancers
How epidemiologic risk factors differ according to receptor status of breast cancer
Tomosynthesis: A new tool for breast cancer detection
Pharmacogenomics in the endocrine treatment of breast cancer
Effects of genetic variability on breast cancer risk and prognosis
Searching for low-penetrance breast cancer susceptibility alleles in East Anglia
Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study
Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer Trial
A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100)
Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study
Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo
Meta- and pooled analysis of the prognostic value of bone marrow micrometastasis on disease outcome in 4,703 breast cancer patients: final results after 10 years of follow-up
Prognostic and predictive value of circulating tumor cells in metastatic breast cancer patients treated with endocrine or chemotherapy
Radiotherapy in breast-conserving treatment for ductal carcinoma in situ (DCIS): ten-year results of European organization for research and treatment of cancer (EORTC) randomized trial 10853
Breast conservation without radiotherapy in low risk breast cancer patients - results of 2 prospective clinical trials of the Austrian Breast and Colorectal Cancer Study Group involving 1,518 postmenopausal patients with endocrine responsive breast cancer
Inhibiting the growth factor receptor (GFR) pathway preserves and enhances the expression of the estrogen receptor (ER) in HER-2/neu (HER2) over-expressing human breast tumors and xenografts
PC-cell derived growth factor (PCDGF/GP88, progranulin) stimulates Her-2 phosphorylation and confers herceptin resistance to Her-2 overexpressing breast cancer cells
Trastuzumab (H: Herceptin®) following adjuvant chemotherapy (CT) significantly improves disease-free survival (DFS) in early breast cancer (BC) with HER2 overexpression: the HERA Trial
Surgical biopsy to diagnose breast cancer adversely affects outcomes of breast cancer care: finding from the National Comprehensive Cancer Network
Genetically engineered human breast tumors in mice
The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8
Optimal duration of adjuvant tamoxifen (TAM) in early breast cancer (EBC): ten year results of a randomized trial (TAM-01) of the FNCLCC Breast Group
Withdrawn by Author
Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding
Analysis of duration of letrozole extended adjuvant therapy as measured by hazard ratios of disease recurrence over time for patients on NCIC CTG MA.17
Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial
The influence of hormone replacement therapy (HRT) on tamoxifen induced vasomotor symptoms
Continued technical results of NSABP B-32: Does a positive sentinel node biopsy require an axillary dissection?
Significance of sentinel lymph node micrometastasis on survival for patients with invasive breast cancer
Prospective study of axillary radiation without axillary dissection for breast cancer patients with a positive sentinel node
The incidence of venous thromboembolism in breast cancer patients
Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer
Genetic alterations associated with early hyperplastic precursors of breast cancer
Ductal carcinoma in situ (DCIS) mammosphere formation; effect of epidermal growth factor (EGF) and notch signalling pathways on self renewal capacity
Cell of origin determines histological type, tumorigenicity and metastatic behavior of breast tumors
Magnitude and laterality of breast cancer risk according to histologic type of atypical hyperplasia: results from the Nurses' Health study
Multi-center validation of the 76-gene prognostic signature in lymph node negative (LNN) primary breast cancer
Association between the 21-gene recurrence score assay (RS) and risk of locoregional failure in node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
A functional luteinizing hormone (LH) receptor polymorphism predicts adverse outcome in premenopausal breast cancer patients
Phenotypes for endocrine resistance can be identified by RNA microarray of sequential biopsies and are more variable than those predicting for tumour response
A reliable new model of estrogen dependent human breast cancer lymph node metastasis
Estrogen receptor alpha antagonizes p53 function by direct interaction-a novel cellular mechanism with a clinical correlate
An estrogen receptor-negative breast cancer subset with over expression of hormone responsive genes
Estrogen receptor-beta has favorable independent prognostic value for estrogen receptor-alpha negative breast cancer patients receiving adjuvant tamoxifen
Statin-using breast cancer patients are less likely to have ER-negative tumors
Better characterization of estrogen receptor (ER) positive luminal subtypes using genomic grade
Comparison of docetaxel/doxorubicin/cyclophosphamide (TAC) versus vinorelbine/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy - first results of the phase III GEPARTRIO-Study by the German Breast Group
Multicenter, randomized phase III study of adjuvant chemotherapy for node positive breast cancer comparing 6 cycles of FE90C versus 4 cycles of FE90C followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 Trial
Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer
Five year follow-up of INT C9741: dose-dense (DD) chemotherapy (CRx) is safe and effective
IL-8 is involved in the development and growth of osteolytic bone lesions
Effects of oral clodronate (BONEFOS®) therapy on bone turnover and skeletal metastases in women with primary breast cancer
Clinicopathological characteristics of young onset breast cancer: initial results from a prospective cohort study
Variants of undetermined significance in BRCA2: protein modeling, loss of heterozygosity, ethnicity, and clinical correlations
Radiation exposure and breast cancer risk for BRCA mutation carriers
Prevalence, spectra and founder effects of BRCA1 and BRCA2 germline mutations in Pakistani breast and/or ovarian cancer families
Screening for BRCA genomic rearrangements in Singapore patients with young onset or familial history of breast or ovarian cancer: identification and characterization of a novel 10.1 kbp deletion
Incidence and histology of ductal carcinoma in situ in BRCA1/2 mutation carriers
Long-term survival (OS) and prognostic factors of BRCA1-associated versus sporadic breast cancer (BC), results of an extended series
BRCA genetic testing and race: the UNC experience
A screening approach to detect hereditary cancer risk in under-served women
Risk reduction choices of women with deleterious BRCA1 and BRCA2 mutations at a single institution
A single mammary stem cell can reconstitute a functional mammary gland
Identification of multipotent breast stem/progenitor cells in mammospheres derived from human normal breast parenchyma and breast cancer tissue
In vitro propagation and characterization of tumorigenic breast cancer cells with stem/progenitor cell properties
Identification of cell-of-origin breast tumour subtypes in inflammatory breast cancer by gene expression profiling
Integrated molecular profiling of human breast cell types and breast cancer cell lines using expression microarrays and array CGH
Inhibitors of Hsp90 induce the degradation of HER2 and inhibit the growth of HER2-dependent breast tumors
Real-time dual-color imaging of trafficking, cellular dynamics, and viability of breast cancer cells in the portal vein
Breast cancer stromal fibroblast cells: in vitro characterization of activity, invasiveness and the effect of transforming growth factor beta 1 (TGF-B1)
Spontaneous fusion of mouse stroma with transformed estrogen receptor-positive epithelium in a solid tumor model of human breast cancer
Genetically modified HER2-specific T cells recognize low and high HER2 expressing breast cancer cell lines
Resistance to erbB targeted therapy in breast cancer
Mammary cancers in mice expressing mutated Rad51
Multi-centre independent validation of a gene prognostic signature for patients with node-negative breast cancer (BC) - final results
Breast tumours with intermediate histological grade can be reclassified into prognostically distinct groups by gene expression profiling
A miniPathway for tamoxifen therapy resistance
Gene expression profiles as predictors of response to neoadjuvant taxotere and adriamycin/cytoxan: a prospective randomized multicenter trial in breast cancer
Predicting response to ixabepilone: genomics study in patients receiving single agent ixabepilone as neoadjuvant treatment for breast cancer (BC)
Affymetrix gene chip profile predicts pathologic complete response to preoperative paclitaxel/FAC chemotherapy in breast cancer
Transcriptional profiling can predict the achievement of a pathologic complete response (pCR) after preoperative chemotherapy (PST) with gemcitabine (G), epirubicin (E) and docetaxel (Doc) in primary breast cancer (PBC) with high accuracy
Measurements of estrogen receptor and reporter genes from microarrays determine receptor status and time to recurrence following adjuvant tamoxifen therapy
Feasibility of gene expression profiling in community hospitals; preliminary results of a pilot study in N0 breast cancer patients
Measurement of gene expression using tissue microarray cores of paraffin embedded breast cancer tissue
Validation of HOXB13, IL17BR and CHDH as predictors of clinical outcome of adjuvant tamoxifen monotherapy in breast cancer
A two-gene expression ratio of HOXB13 and IL-17BR for prediction of recurrence and survival in women receiving adjuvant tamoxifen
Axillary recurrence after negative SLN biopsy
Low local-regional failure rates in selected breast cancer patients with tumor-positive sentinel nodes who do not undergo completion axillary dissection
Additional axillary metastases and stage migration in patients with micrometastases or submicrometastases in sentinel lymph nodes
Predicting negative axillary lymph node dissection in patients with positive sentinel lymph node biopsy: can a subset of patients be spared axillary dissection?
A prospective evaluation of a new technique using aponeurosis padding without vacuum drainage to reduce morbidity in patients undergoing axillary node dissection for localized breast cancer (LBC)
Optimizing the total skin-sparing mastectomy
The effectiveness of per-operative use of human surgical sealant - 'Quixil' in reducing the post operative seroma formation in breast cancer patients
Intraoperative digital specimen mammography: improving efficiency without loss of accuracy
The impact of radiotherapy on capsule formation and aesthetic outcome after immediate breast reconstruction using biodimensional anatomic expander implants
Early stage breast cancer in young women: does selection of surgical treatment impact overall survival?
Novel molecular diagnostic method for rapid evaluation of lymph node metastasis in breast cancer
The combination of frozen section and enhanced polymer one-step staining immunohistochemistry for the intraoprative diagnosis of sentinel nodes of breast cancer
Comparative study of lymphedema with axillary node dissection and axillary sampling with radiotherapy in women undergoing breast conservation surgery for breast cancer
Timing of sentinel node biopsy for patients undergoing mastectomy with immediate reconstruction
Does a negative lymphoscintigram predict for sentinel lymph node positivity
Sonographic evaluation of axillary lymph nodes using realtime sonoelastography
Analysis of sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy
Sentinel lymph node biopsy for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy
The incidence of axillary nodal metastases in older women with small non-high grade breast tumours
A standardized surgical technique for mastoscopic axillary lymph node dissection
Intra-operative sentinel lymh node assessment of 193 patients with invasive breast carcinoma: does sentinel lymph node intraoperative examination reduce the complementary axillary lymph node dissection?
Optical assessment of axillary lymph nodes in breast carcinoma
Clip migration after 11G vacuum-assisted breast biopsy: retrospective review of 447 clips and implication in breast surgery
Optical biopsy: breast cancer diagnoses at the speed of light
Serum EGFR and HER-2 expression in primary and metastatic breast cancer patients
Persistence of isolated tumor cells (ITC) in bone marrow (BM) of breast cancer patients predicts increased risk for relapse - results of pooled European data
Molecular profiling of disseminated tumor cells in peripheral blood of breast cancer patients
Monitoring circulating breast cancer cells by quantitative real time RT-PCR
Peri-operative assessment of circulating tumor cells in blood, disseminated tumor cells in bone marrow, and tissue gene signatures in patients with primary breast cancer
Detection of circulating tumor cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 mRNA in breast cancer patients
Detection and monitoring of circulating tumor cells (CTCs) by CK-19 mRNA in breast cancer patients treated with neoadjuvant chemotherapy: a marker of early recurrence
Isolation and gene expression profiling of bone marrow disseminated tumor cells from women with locally advanced breast cancer
Prospective central assessment of HER-2 status by FISH is not a predictive factor for pathologic complete response (pCR) in 648 breast cancer patients treated preoperatively with an anthracycline / taxane based regimen in the multicenter GeparTrio Trial
Estrogen receptor genotypes predict the response of serum cholesterol to tamoxifen treatment
Withdrawn by Author
Withdrawn by Author
Inhibin A and B as predictive markers for chemotherapy-induced premature ovarian failure (POF) among premenopausal women with early stage breast cancer (ESBC)
TWIST2 gene expression predicts for chemo-sensitivity in patients from two randomized trials of adjuvant FAC/FEC
Molecular determinants of aromatase inhibitor sensitivity in primary breast cancer
Simultaneous and quantitative detection of multiple biomarkers in human breast cancers using semiconductor multicolor quantum dots
Role of hypoxia-inducible factor 1 in predicting treatment efficacy in primary chemo-endocrine therapy in human breast cancer
Elevated plasma TIMP-1 level predicts decreased response and survival in metastatic breast cancer
High tumor tissue levels of tissue inhibitor of metalloproteinases-1 are associated with resistance to chemotherapy in patients with metastatic breast cancer
Can diffuse optical spectroscopy predict the final pathological response of neoadjuvant chemotherapy?: a retrospective pilot study
HIGH expression of the microtubule-associated protein, tau, strongly predicts improved progression free and overall survival in patients with metastatic HER-2-negative breast cancers treated with docetaxel and vinorelbine plus filgrastim
Immunohistochemical detection of ER in breast cancer using the new rabbit monoclonal anti-ER antibody SP1 better predicts survival and response to tamoxifen than the mouse monoclonal antibody 1D5: a tissue microarray study of 4620 cases
INFLUENCE of hormone receptor status on axillary lymph node (ALN) pathologic complete response (pCR) rates in patients with cytologically confirmed ALN metastases prior to primary chemotherapy for breast cancer
MR spectroscopy of breast cancer tissue used for tumor classification and lymph node prediction
Incidence of monosomy of chromsome 17: a potential pitfall in assessing HER-2 gene amplifiaction
Is there a regimen-specific gene signature predicting for pathological complete response after neoadjuvant chemotherapy in hormone-negative breast cancer patients? A microarray substudy of 101 patients included in EORTC 10994/BIG 00-01 Trial
Identification pharmacogenomic markers for predicting paclitaxel-related toxicity in breast cancer patients treated with neoadjuvant chemotherapy
Predictors of early ipsilateral breast tumor recurrence following breast conservation therapy
Analysis of thymidylate synthase, methylenetetrahydrofolate reductase and IVS14+1 dihydropyrimidine deshydrogenase gene polymorphisms in advanced breast cancer patients receiving capecitabine as monotherapy
Src as a novel molecular biomarker for response to neoadjuvant chemotherapy with sequential doxorubicin and docetaxel in high-risk breast cancer
Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline-containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting
Evaluation of thymidine phosphorylase (TP) in primary breast cancer treated with docetaxel (D) and capecitabine (C)
Methods to optimize tissue collection and assay performance from 16-gauge core biopsies in the I-SPY Trial
Predictive markers for 5-FU resistance in metastatic breast cancer
Clinical characteristics and molecular markers predicting the development and outcome of breast cancer brain metastases
Recurrence in ductal carcinoma in situ (DCIS) after complete microsurgical local excision is predicted by a high proliferation index and HER2/c-erbB2 status
Identification and multicentric validation of a metagene-based molecular predictor
Predictivity of serum HER-2/NEU and EGFR concentrations for clinical outcome to the monocloncal anti-HER/2-neu antibody trastuzumab plus combination chemotherapy in metastatic breast cancer
Validity of DNA-methylation marker PITX2 to predict risk of recurrence in lymph node-negative hormone receptor-positive breast cancer patients: a transfer study
Effect of systemic therapy following surgery on outcome in patients diagnosed with an ipsilateral breast tumor recurrence
Identification of prediction marker for drug response in gene expression analysis combined with the pharmacodynamic profile in breast cancer patients treated with neoadjuvant chemotherapy
Association of MRI morphological phenotype with early and final responses in AC followed by taxane + carboplatin +/− trastuzumab regimen
Elevated serum MCP-1 level is associated with favorable clinical prognostic factors and immune response and can be induced by a HER2/neu (E75) vaccine in breast cancer patients
The role of the angiogenic marker, endoglin, as a predictor of response to neoadjuvant chemotherapy in primary breast cancer
Early predictive value of positron emission tomography with [18F]-fluorodeoxyglucose for the pathologic complete response of primary tumor in breast cancer patients treated by neoadjuvant chemotherapy
Predicting distant metastasis after local recurrence (failure) in women treated by breast conserving treatment
Gene expression profiles in white blood cells of patients with breast cancer - correlation with detectability of tumor by mammographic screening
Expression levels of estrogen receptor (ER) gene and three ER-related genes in metastatic ER-positive breast cancer compared with response to endocrine therapy
E7389, A Novel Anti-Tubulin, is Safe and Effective in Patients with Refractory Breast Cancer
A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer
Efficacy and tolerability of gefitinib in oestrogen receptor negative and tamoxifen resistant oestrogen receptor positive locally advanced or metastatic breast cancer
Phase II study of SU11248, a multitargeted tyrosine kinase inhibitor (TKI) in patients (pts) with previously treated metastatic breast cancer (MBC)
A phase I/II study of AG-013736, an oral anti-angiogenesis agent, in combination with docetaxel in patients (pts) with metastatic breast cancer (MBC)
Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3-arm, phase 2 study
Phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC®T) in Her-2/neu negative early breast cancer patients with positive axillary lymph nodes: Interim analysis of the BCIRG 005 study
A phase 2b multicenter evaluation of the safety and efficacy of TOCOSOL® paclitaxel (TOC-P) as initial treatment of patients with metastatic breast cancer (MBC)
Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with ErbB2 FISH-amplified advanced or metastatic breast cancer
ZK-EPO, a novel synthetic epothilone B analog, significantly inhibits tumor growth in both non-resistant and resistant breast cancer models
A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab
Long term survival with no apparent toxicity observed with a novel cisplatin-incorporated polymeric micelle, NC-6004, in the MCF-7 breast cancer model
Combination of a prenylation inhibitor and either classical chemotherapy or a M-TOR inhibitor: potential clinical implications
Effects of the potent telomerase template antagonist GRN163L in breast cancer
Anticancer influence of a methioninase containing fusion protein targeted to the urokinase receptor on breast cancer cells
The use of p53-mediated alteration of microtubule dynamics to sensitize breast cancer to vinca alkaloids
A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer
Unexpected hepatic toxicity after primary treatment with gefitinib and docetaxel in patients with locally advanced breast cancer
A phase I/II study of capecitabine (X) combined with oral vinorelbine (N) as first- or second-line chemotherapy in patients (pts) with locally advanced breast cancer (MBC)
Selective inhibition of ADAM metalloproteases as a novel approach for modulation ErbB pathways in cancer
Phase I/II trial and pharmacokinetic/pharmacodynamic analysis exploring a synergistic interaction between the histone deacetylase inhibitor, valproic acid and the anthracycline, epirubicin
Multicenter phase 2 study of XRP6258 in taxane-resistant metastatic breast cancer (MBC) patients (pts)
Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
High efficacy of the sigma antagonist rimcazole against an endocrine insensitive, p53 mutant MDA-MB-231 xenograft preclinical model
A phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results
A phase I/II study of oral capecitabine (X) and vinorelbine (V) as second- or -third line chemotherapy in anthracycline/taxane pretreated patients (pts) with metastatic breast cancer (MBC)
Phase II, open label study of SB-715992 (Ispinesib) in subjects with advanced or metastatic breast cancer
Phase I study of irinotecan followed by capecitabine in patients with advanced breast carcinoma
Plasma kinetics and uptake of a cholesterol-rich microemulsion (LDE) associated to a derivative paclitaxel by neoplastic breast tissue
Preliminary results of phase I trial of carboplatin (CP) in combination with ABI-007 administered weekly or every 3 weeks in patients (pts) with solid tumors
The conjugation of doxaliform to alpha(v) beta3 (αvβ3)-targeting peptides provides a potential therapeutic alternative for the management of αvβ3-overexpressing breast carcinomas
Rifampin reduces exposure to sunitinib malate (SU11248) in Caucasian and Japanese populations
Trastuzumab (T) and KOS-953 (17-AAG) is feasible and active in patients (pts) with metastatic breast cancer: preliminary results of a phase 1/2 study
c-jun activation is associated with angiogenesis in invasive breast cancer
Lymphangiogenesis and human breast cancer
A histomorphological study of tumor lymphangiogenesis in inflammatory and non-inflammatory breast cancer
Vascular endothelial growth inhibitor (VEGI), an anti-angiogenic factor, in human breast cancer
Tamoxifen increases matrix metalloproteinase 2 and 9 activities and endostatin levels in breast cancer tumors in vivo
Lack of correlation between microvessel density & pericyte coverage index within breast cancer biopsies & functional dynamic contrast-enhanced MRI-derived vascular parameters
Role and prognostic relevance of hypoxia inducible factor 1α and its downstream targets in fibroepithelial tumours of the breast
Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes
MEK5-ERK5 signaling promotes estrogen-independent tumorigenesis of breast carcinoma cells
The most common integrin ITGA2 haplotype (807C_1648G, "wildtype") is associated with decreased breast cancer risk
Invasive lobular carcinoma and the high grade variant pleomorphic lobular carcinoma: molecular characterization
Classic lobular breast carcinoma: comprehensive molecular genetic analysis
Is aberrant hypermethylation an early event in breast cancer?
SNP microarray analysis of genomic alterations in infiltrating ductal carcinoma and infiltrating lobular carcinoma
Comparison between matched pairs of primary breast cancer and distant metastasis using array CGH
C-MYC expression correlates with atypia and malignancy in early breast lesions associated with microcalcifications detected by routine mammography
Breast cancer metastasis-free survival and its association to a common hereditary gene polymorphism of cyclin D1
Apocrine metaplasia and the development of ER-negative breast cancer
Molecular alterations in columnar cell lesions of the breast
The evaluation of the breast imaging in clinical complete response patients after primary chemotherapy
An electronic data registry for evaluating fulvestrant treatment in patients with advanced breast cancer
A phase II and biologic correlative study investigating anastrozole (A) in combination with geftinib (G) in post menopausal patients with estrogen receptor positive (ER) metastatic breast carcinoma (MBC) who have previously failed hormonal therapy
Oncologist-patient discussion of adjuvant hormonal therapy: results of a linguistic study focusing on patient adherence/persistence
Novel DJ compounds cause reduction in human breast tumors
Supraclavicular failure in patients with 1 to 3 positive axillary lymph nodes treated with breast conserving surgery and breast irradiation, with or without supraclavicular node irradiation
Cyclopamine inhibits breast cancer cell growth via hedgehog network-dependent and independent mechanisms unrelated to cholesterol trafficking
Urinary metalloproteinases: a novel non-invasive methodology for breast cancer risk assessment
Circulating tumor marker discovery using proteolytic peptide profiling and isotope-coded affinity tags
The relationship between circulating concentrations of Her-2, C-reactive protein and survival in patients with primary operable breast cancer
Evaluation of immunoassay and RT-PCR methods for detection of the NMP66 complex for diagnosis of breast cancer
Increased levels of the circulating growth factor GP88 in the serum of breast cancer patients
Circulating tumor cells in adjuvant breast cancer patients
Methylated genes in ductal lavage fluid from women with known breast cancer undergoing mastectomy
Glycan array identifies specific signatures of anti-glycan autoantibodies in sera of breast cancer patients: diagnostic, prognostic and therapeutic opportunities
Serum profiling predictive of invasive breast cancer
Patient detected breast cancer not seen on mammography
Serum proteome of breast cancer: a group of proteins related to the invasive stage
Ductal epithelial impedance spectroscopy; a new approach to breast cancer diagnosis
New biomarkers in the detection of breast cancer in nipple aspirate flui (NAF), using surface enhanced laser/desorption ionisation coupled with time-of-flight mass spectrometry (SELDI-TOF/MS) in combination with artificial intelligence methods
Concurrence of contralateral breast cancers for estrogen and progesterone receptor status and mode of detection
Variation in protein expression patterns of nipple aspirate fluid comparing women with breast cancer and healthy women using time-of-flight mass spectrometry
Comparison of FLT-(18F) and FDG-(18F) to visualize cancer spread while staging locally advanced breast cancer with PET/CT: preliminary data
Combined mammography and breast ultrasound are required for a good accuracy of BI-RADS 4/5 results - findings of a breast imaging reference center
Improving the Case Definition of Inflammatory Breast Cancer
Concordance of HER2 and hormone receptor expression in primary and recurrent breast cancer
Proliferating macrophages appear to be uniquely associated with large, palpable DCIS and high grade invasive cancers
Mammaglobin identification by immunohistochemistry and reverse transcriptase polymerase chain reaction to increase detection of breast cancer metastases
Reliability of core biopsy in pre-operative diagnosis of papillary lesions of the breast
Are so-called "intracystic" papillary carcinomas of the breast in situ or invasive lesions?
A nomogram to predict for malignant diagnosis of solid lesions in a one-stop breast unit
Genomic alterations as a pathological aid to classifying ductal carcinoma in situ
Peptide breast cancer biomarkers detectable through blood tests
Intra-operative touch preparation cytology; does it have a role in re-excision lumpectomy?
Response in gene expression profile to bevacizumab treatment in patients with inflammatory and locally advanced breast cancer
Cost-benefit estimates of adjuvant (Adj) trastuzumab (herceptin, H) for early breast cancer (BrCa)
A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer
A phase II trial of trastuzumab (H) plus capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer (MBC)
Weekly paclitaxel (PCT) ± trastuzumab (T) as first-line therapy of patients (pts) with HER-2/NEU positive metastatic breast cancer (MBC): final results of a multicenter randomized phase IIb trial
Capecitabine and trastuzumab: a phase II study in HER2-overexpressing metastatic breast cancer (MBC) patients pretreated with anthracyclines and/or taxanes
Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (Erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with advanced solid tumors
A phase I-II study of trastuzumab, gefitinib, and docetaxel as first line chemotherapy in patients with HER-2 overexpressing stage IV breast carcinoma
Effect of trastuzumab treatment as first-line on metastatic breast cancer: final results of the French HERMINE cohort after 2-year follow-up (n=221)
Improved breast cancer specific survival (BCSS): the impact of adjuvant systemic therapy
Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administered as a component of adjuvant therapy?
Final analysis of a planned comparison of menopausal symptoms in 1618 patients receiving either exemestane (E) or tamoxifen (T) in a blinded adjuvant hormonal study
Impact of letrozole on quality of life in post-menopausal women with early breast cancer: does age matter?
Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/Amplified breast cancer (BCA)
NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor
Bone mineral density loss in premenopausal women given adjuvant chemotherapy for early breast cancer is independant of effects on ovarian function
Health-related quality-of-life and psychological distress of breast cancer patients after surgery during phase III randomized trial comparing further tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1 to 4 years: N-SAS BC 03
Leuprorelinacetate 3 month-depot versus CMF as adjuvant treatment in receptor- and node-positive premenopausal patients with breast cancer: long term results of the TABLE-Study
The effects of atamestane and toremifene alone or combined on bone, serum lipids and uterus, comparing them to letrozole in the ovariectomized rat
Letrozole did not worsen quality of life relative to placebo in post-menopausal women with early breast cancer: results from the US subjects of the MA-17 study
Withdawn by Author
Impact of Oncotype DX™ on decision making in breast cancer clinical practice
Economic evaluation of switching to exemestane at 2.5 years versus continuing tamoxifen as adjuvant therapy in early breast cancer: a Canadian perspective
Menostasis subsequent to individually dose-tailored fluorouracil-epirubicin-cyclophosfamide chemotherapy for early breast cancer
Initial results from the LEAP Study: the first direct comparison of safety parameters between aromatase inhibitors (AIs) in healthy postmenopausal women
LH-RH analogues, tailored adjuvant chemotherapy and total estrogenic block in patients with estrogen receptor positive (ER+) tumors, preserve ovarian function and improve the clinical outcome of young women with early breast cancer
Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer from a US perspective
Breast cancer navigator program: clinical trial access, recruitment and enrollment at a large county hospital
Gynecologic interventions during adjuvant therapy with anastrozole or tamoxifen: results from the ATAC trial
Side effects in treatment with FEC (5-fluorouracil, epirubicin and cyklophosphamide) in standard doses compared to tailored doses, based on hematological toxicity, for primary breast cancer. Results from the Scandinavian Breast Group 2000-1 Study
Cost-effectiveness analysis of letrozole versus tamoxifen as initial adjuvant therapy in hormone-receptor positive postmenopausal women with early breast cancer: the UK perspective
Positive cooperative effects of gefitinib, chemotherapeutics and a breast cancer resistant protein inhibitor on cell growth in a fulvestrant-resistant estrogen receptor alpha negative MCF-7 cell model
Upregulation of HER-2/neu is independent of the menopausal status of primary breast cancer patients: plasma results from a prospectively randomized trial comparing dose-intense chemotherapy with G-CSF support to 3-weekly chemotherapy for adjuvant therapy of nodal-positive (1-3 LN) breast cancer
Predictors and temporal trends of adjuvant endocrine therapy use in breast cancer
Fatigue and metabolic changes in patients with early breast cancer (EBC) receiving anthracycline-based adjuvant chemotherapy, a longitudinal prospective study
Chemotherapy-induced amenorrhea (CIA) in patients treated with adjuvant CEF/CMF or EC/docetaxel: analysis from a phase III randomized EC/Doc Trial
The development of a prediction tool for chemotherapy-induced anemia in breast cancer patients receiving adjuvant chemotherapy
Long-term follow-up of sequential dose-dense chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in breast cancer patients with 4-9 positive nodes: final results of a phase I/II study
A feasibility study of docetaxel in combination with anthracycline and cyclophosphamide or docetaxel followed by anthracycline plus cyclophosphamide in adjuvant therapy for operable breast cancer with positive axillary lymph nodes: CHN TAX 619
Does switching to letrozole improve hot flushes, mood and quality of life in tamoxifen intolerant patients?
Five years use of aromatase inhibitors (Ais) in the clinical practice. Results from the NORA Study
Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible
Epirubicin, paclitaxel and CMF as adjuvant treatment in node positive patients with operable breast cancer. Safety analysis of a randomized phase III study comparing two dose-dense sequential regimens
Adjuvant dose-dense (3 FEC 100 followed by 3 docetaxel every 2 weeks) regimen is not feasible. Results of the FNCLCC-PACS 06 Study
Benchmarking the quality of adjuvant systemic therapy for breast cancer using multicenter data systems and practice guidelines: strengths and limitations
Pilot study of dose dense doxorubicin + cyclophosphamide followed by ABI-007 in patients with early stage breast cancer
Late adriamycin-related cardiotoxicity of dose-dense and - intense sequential doxorubicin (A), paclitaxel (T) and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer
A prospective assessment of variables contributing to reduced relative dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy
Initial phase II results from 3 dose dense docetaxel pilots in early stage breast cancer
Intra-operative tissue characterization probe as a potential tool for surgical margin assessment
A novel method for reconstruction of immediate partial mastectomy defects
Measuring quality in breast reconstruction - Liverpool scoring system
Withdrawn by Author
Early results of nipple-areola-sparing subcutaneous mastectomy (NASSM) with complete resection of the retroareolar ductal system (RDS)
Optimal timing of surgical intervention for the primary tumor in stage IV breast cancer patients improves outcome
A new latissimus dorsi muscle flap technique in oncoplastic surgery -the Bayreuth modification
Oncoplastic technics for breast conservative surgery with ablation of nipple-areolar complex for central breast cancers
Evaluation of local recurrence following surgical treatment of screen-detected breast cancer in Wales diagnosed between 1989 and 2003
The use of intrapleural analgesia following mastectomy and immediate lattisimus dorsi myocutaneous flap breast reconstructions
Combination therapy of Ad-mda7 and herceptin synergistically increases apoptosis in Her2/neu over expressing breast cancer cells
Reverse phase protein array in breast cancer classification
Ras-mediated post-transcriptional regulation of connexin43 expression: interplay between mRNA 3′ and 5′ untranslated regions
Constitutively active type I insulin-like growth factor receptor signaling induces transformation and epithelial-mesenchymal transition in mammary epithelial cells
Involvement of NF-kappaB in inflammatory breast cancer through the induction of epithelial to mesenchymal transition
Transcriptional analysis of factors affecting estrogen regulation in fine needle aspirates
Regulation of steroid sulfatase gene expression in breast cancer
Regulation of bcl-2 by the BP1 homeotic protein in breast cancer cells
p53 codom 72 polymorphism and the correlation with breast cancer
Occludin is aberrantly expressed in human breast cancer
GRB-7 promotes HER-2/Neu mediated signaling and tumor formation in breast cancer cells
Clinical and pathological characterization of basal-like breast cancer
Influence of pico-tesla range electromagnetic fields on mammary carcinoma protein expression profiles
Protein acetylation and hormone-independent breast cancer
Diet and global DNA methylation in breast cancer
Molecular pathogenesis of breast cancer in women of African ancestry
Notch signaling is altered in breast cancer and is a potential therapeutic target
Activated c-Src in ductal carcinoma in situ (DCIS) correlates with high tumour grade, high proliferation and HER2 expression
The pure prolactin receptor (PrlR) antagonist Δ1-9 G129R-hPrl reduces breast cancer clonogenicity and enhances doxorubicin cytotoxicity in vitro
The potential of MRI relaxation times to predict biological aggressiveness of breast cancer
Withdrawn by author
Chinese herb lycium barbarum inhibits growth of hormone responsive human breast cancer cells by down-regulating C16∝-hydroxylation pathway of estradiol metabolism
Haemangiogenesis and lymphangiogenesis in the primary tumor and in lymph node metastases of breast cancer: a comparative histomorphometrical study
Phenotypic characterization of inflammatory breast cancers on tissue microarrays: a study of 109 cases with 25 proteins
PIK3CA mutations in breast cancer: an attractive target for small molecule inhibitors and a potential biomarker for chemoresistance
Nectin-3: a putative tumour suppressor in human breast cancer
Microarray analysis of breast tumor tissue from African American and Ugandan women show that high risk biological features are similar
Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen
Outcome and prognostic factors among patients with node-negative invasive breast carcinoma that is one centimeter or less in size (stage 1; T1a,b N0 M0): the University of Texas M. D. Anderson Cancer Center experience
A novel prognostic immunohistochemical biomarker panel for estrogen receptor expressing breast cancer
Statistical and pathway analysis of multiple prognostic gene signatures in lymph node negative (LNN) primary breast cancer
Basal-like breast carcinomas: clinical outcome with chemotherapy
A prospective risk model for neutropenic complications in early-stage breast cancer patients receiving adjuvant chemotherapy
The percentage of positive/dissected nodes is a useful prognostic indicator of postmastectomy recurrence and mortality
The prognostic impact of the axillary lymph node ratio in patients with micrometastatic node-positive breast cancer
Ki-67/MIB-1 as prognostic marker in women with early breast cancer: a meta-analysis of published studies involving 10.958 patients
Clinicopathologic significance of the basal-like subtype in breast cancer: comparison with hormone receptor and Her2/neu expressing phenotypes
Prognostic value of pathologic complete response after primary chemotherapy in patients with hormone receptor-positive breast cancer
Breast cancer characteristics and 10 year survival in young women
Prognostic significance of CDKs profiling in breast cancer
The survival analysis of immunohistochemically defined basal and luminal subtype of breast cancer
Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer
Predicting relapse in estrogen receptor (ER) positive breast cancer (luminal) subgroups treated with adjuvant tamoxifen
Leptin receptor isoforms (OBR-L and OBR-S) expression in breast cancer and relation with clinical outcome
Using AQUA™ and tissue microarrays for discovery of a minimal set of multiplexed markers to subclassify breast cancer
Predicting prognosis in early stage primary breast cancer using a five biomarker panel and image assisted immunohistochemistry (IHC) scoring
Breast cancer phenotype associated with a propensity for central nervous system (CNS) metastases
Lymph node ratio as a prognostic factor in metastatic breast cancer
Prognostic value of uPA and PAI-1 mRNA expression in primary breast cancer
Breast cancer of the lower inner quadrant is associated with an increased mortality risk among women with early stage disease
Risk factor analysis of early metastatic relapse for postmenopausal patients treated with tamoxifen
Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen
C-kit expression in high-risk breast cancer treated with high-dose (HD) or conventional dose-dense chemotherapy: results of multivariate analysis from the WSG-AM-01 phase III trial
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen treated estrogen receptor positive breast cancer
Prognostic value of Ki-67 in lymph node-negative breast cancer and the usefulness of a combination of Ki-67 and the St. Gallen classification
Evaluation of TGF-α expression and prevalence of EGFR and HER2 kinase domain mutations in breast cancer
Detection and prognostic significance of HER2 mRNA-positive cells in the peripheral blood of patients with operable breast cancer
HER-2/neu is associated with axillary nodal invasion in breast cancers expressing both hormone receptors
β1 integrin expression is prognostic for overall and disease-free survival in breast cancer
CSF1 expression signature identifies a subset of breast carcinomas and influences outcome
Confirmation of an ER negative PR positive phenotype by quantitative PCR
Disease free survival (DFS) of breast cancer patients with invasive mucinous/tubular (M/T) carcinomas vs invasive ductal/lobular (D/L) carcinomas relative to the grade of the tumor
Identifying univariable and multivariable correlates of HER2 amplification
Hepsin expression is inversely correlated with patient prognosis in human breast cancer
The androgen receptor gene polymorphisms in human breast cancer: short CAG repeats are associated with lymph node involvement
The distribution of EGFR mRNA expression in 247 breast carcinomas and its relationship to ER mRNA expression
CX chemokine receptor 4 (CXCR4) membrane staining is an independent prognostic factor in primary breast cancer
Plakoglobin (γ-catenin) is a prognostic marker in breast cancer
C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu
Sprouty 4 expression is decreased in node-negative breast cancer and intimately related to expression of cell cycle proteins
p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma
Comparison between the 5th and 6th American Joint Committee on Cancer(AJCC) staging system in 1,275 breast cancer patients
Pretreatment plasma leptin and leptin receptor levels in metastatic breast cancer
Identification of a mechanistically-defined panel of mRNA markers associated with long-term prognosis of node-negative breast cancer
Cyclin E2 mRNA expression and metastasis-free survival in untreated node-negative breast cancer patients
Survivin is a predictor of poor outcome in breast cancer
Prognostic value of p53 specific mutations in low-risk HER-2/neu negative primary breast cancers
Prognostic and predictive value of CK-19 mRNA-positive cells detected by real time RT-PCR in the peripheral blood of patients with axillary lymph node-negative breast cancer receiving adjuvant chemotherapy
Prognostic factors predicting survival of metastatic breast cancer patients: analysis of 591 patients
Expression of leptin and leptin receptor in breast cancer are associated with aggressive histology, distant recurrence and survival
Comparison of outcomes of hormone receptor (HR) negative, and HER2 negative (triple negative, TN) to HER2+ breast cancer (BC) patients (pts): impact of HER2 status
Expression of estrogen receptor and Ki-67 as prognostic factors for locoregional recurrence after breast conserving surgery
Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastases
Patterns of care in patients included in the TEAM (tamoxifen and exemestane adjuvant multicentre) trial. Differences among the participating countries
Benchmarking patterns of utilization among breast cancer patients
Comorbidity risk model for patients with breast cancer
Decreasing incidence of Paget's disease of the breast among American women
Breast cancer characteristics at diagnosis among Arab-American women compared to European- and African-American women in the Detroit SEER registry
Pregnancy after breast cancer in Western Australian women
General population rates of selected conditions and events recorded in breast cancer hormonal therapy trials
Comparing improvements in survival for older and younger breast cancer patients
Variation in breast disease co-occurrence frequencies between pre- and post-menopausal women
Distinct breast cancer incidence and survival patterns according to histopathology: analysis of the NCI's SEER database
Incidence and risk factors for lymphedema after axillary lymphadenectomy for breast cancer
Trends in breast cancer incidence in Scotland: the influence of screening and deprivation
registHER: treatments and clinical outcomes from a prospective observational cohort study of patients with HER2-positive metastatic breast cancer
Do changes in ER status explain improvements in survival?
The incidence and outcomes of gestational breast cancer in Western Australian women
A systematic review and descriptive analysis of inflammatory breast cancer clinical trials
Breast cancer in young women age < 36 years: a retrospective analysis of prognostic factors in 908 patients in 8 french instituitions. GETNA Group
A survey of breast cancer screening activity and beliefs among Arab women in the Detroit metropolitan area
Relationship between educational level and breast cancer
Dying with breast cancer - an audit
Patient satisfaction in breasst cancer care - results from the patient satisfaction and quality in oncological care study (PASQOC® 2004)
Efficacy of internet-based education for patients with post breast therapy pain syndrome and lymphedema
Neoadjuvant vs. adjuvant chemotherapy: young women's experiences, attitudes and information needs after diagnosis
Does inequality of access affect whether patients have breast reconstruction after mastectomy? A survey of breast care nurses in the South West region of the UK
Alamo breast cancer foundation patient advocate program
Knowledge and practice of breast-self examination in underserved population (Goiania - Brazil)
Assessing the needs of women with advanced (metastatic) breast cancer
Creating a DNA bank for pharmacogenomic epidemiology: the Friends for Life study
Mucositis - an evolving problem
Emerging solutions: moving from informed consent to informed choice, an advocate collaborative model
Differential gene expression in normal breast tissue from African American and Caucasian women
Racial disparities in the utilization of adjuvant chemotherapy and radiation therapy in elderly patients with early stage breast cancer: a population-based study
Delays and receipt of adjuvant chemotherapy and radiation therapy in breast cancer patients: a population-based study
Impact of ethnicity on conditional survival of breast cancer patients: analysis from the SEER database
Low socio-economic status African-American, Hispanic & white women with breast cancer demonstrate similar hormone receptor status, tumor grade & survival
Racial/ethnic differences in delay in obtaining medical care for breast symptoms
Factors affecting breast cancer screening practices among African American women in Western New York
Racial differences do not predict response to induction chemotherapy
Eligibility to the study of tamoxifen and raloxifene (STAR) by ethnicity in New Mexico (NM)
Breast cancer treatment and survival in African Americans and Caucasians
Understanding racial differences in outcome from metastatic breast cancer (MBC): a pooled analysis of Cancer and Leukemia Group B (CALGB) 9342 and 9840
Does screening underserved/minority women for breast cancer under the age of 50 make a difference?
Hormone replacement therapy (HRT) may not increase the incidence of breast cancer in Japan
Cyclophosphamide and 5-fluorouracil: an alternative neoadjuvant chemotherapy for patients with stage II breast cancer in underdeveloped countries
A comparison of clinicopathological features and molecular markers in British and Nigerian women with breast cancer
The SNP309 HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene
Activation of nuclear factor (NF)-kB is linked to resistance to neoadjuvant chemotherapy in breast cancer patients
Altered prostaglandin-signalling in hormone resistant breast cancer by microarray and real time PCR validation
Gene expression profile of ATP binding cassette (ABC) transporter in breast cancer patient in relation to the response to neoadjuvant chemotherapy
Elevated c-met expression accompanies endocrine resistance in MCF7 breast cancer cells and promotes in vitro cell migration and invasion
A novel role for the ASK/JNK pathway in mediating Akt-induced endocrine therapy resistance
Zinc-dependant stimulation of Src, EGFR and IGFR signalling pathways in tamoxifen-resistant breast cancer and the role of zinc transporters
Overexpression of c-Myc confers anti-estrogen resistance in breast cancer cells
Expression patterns of 5-fluorouracil metabolism-related genes in breast cancer using focused DNA array
Tamoxifen failure in breast cancer: use of gene expression array and immunohistochemistry tissue micro arrays to define a molecular signature of tamoxifen resistance
Therapeutic modulation of anti-estrogen resistance through histone deacetylase inhibition
SERM-resistant breast cancer is cross-resistant to tibolone
Genetic counseling and testing for hereditary breast cancer in underserved women
German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer
Actively approaching breast cancer patients for genetic counseling during adjuvant radiotherapy: does it harm?
Genetic testing for BRCA1 and BRCA2 mutations in the Hispanic population
Determinants in the uptake of genetic testing for BRCA1/2 mutations
Breast cancer risk management choices by women with inherited breast cancer predisposition: a preliminary analysis
Characteristics of pre-menopausal invasive breast cancer and age-associated risk of breast cancer in BRCA1 and BRCA2 mutation carriers compared with non-carriers (BRCA0)
Patients' perceived breast cancer risk and psychological distress: can oncologist-based counseling achieve durable improvements?
Risk-reducing strategies in breast cancer: a decision analysis
BRCA1 and BRCA2 mutations in a South American population
A strong family history of breast cancer increases the use of systemic treatment among patients with early-onset breast cancer: results from a population-based study
Preliminary results of a randomized phase IIb double-blind 2×2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention
Celecoxib downregulats estrogen receptor expression in breast tissue of women at increased risk for developing breast cancer
Chemopreventive efficacy of new RXR specific retinoids against mammary cancers and correlations with shortterm biomarkers
Reproducibility of ductal lavage findings in high-risk women
Bone turnover by osteocalcin and risks of breast cancer and fracture: a prospective study
Chemopreventive effects of the EGFr inhibitor Iressa in the methylnitrosourea (MNU) - induced model of mammary carcinogenesis
Breast endoscopy in the evaluation of individuals in a high-risk breast cancer clinic
Chemopreventive effects of the statins, lipitor (Atorvastatin) and lovastatin, in the methylnitrosourea (MNU) induced model of mammary carcinogenesis
Curcumin induces cell cycle arrest and apoptosis in an in vitro model for hormonally non-responsive ductal carcinoma in situ
Effect of estrogen deprivation on proliferation marker Ki-67 and minichromosome maintenance protein-2 (Mcm-2) in normal postmenopausal breast tissue: potential biomarkers for chemoprevention
Association of RARβ2, ER, BRCA and p16 promoter methylation with cytologic atypia in random periareolar fine needle aspiration (RPFNA) breast tissue of asymptomatic women at high risk for breast cancer
Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by body mass index (< 25 and ≥ 25 kg/m2)
Identification of genes modulated by LGD1069, a rexinoid that prevents mammary tumorigenesis
Activation of ATM and p53 in mammary gland epithelial cells as a possible breast cancer prevention model
Induction of apoptosis in the absence of p53: implications for chemoprevention for ER-negative breast cancer
Expression of prostaglandin E2 receptor, EP1, in breast cancer
Counceling and care combined with breast self examination training as motivation strategy for breast cancer awareness and participation in breast cancer screening programs
Anticarcinogenic effects of citrus auraptene on rat breast cancer
A case-control study evaluating the association of purposeful physical activity, body fat distribution and steroid hormones on pre-menopausal breast cancer risk
The controversy of annual mammographic screening (AMS) for 40 to 69y-o women of Brazilian cohort of 10.000 underserved women
Tubular carcinoma: outcomes analysis of favorable breast cancer treated with breast conserving therapy
Decision-making process for early-stage breast cancer is surgeon driven
Adjuvant chemotherapy in stage II node positive male breast cancer
Long-term risk of cardiovascular disease in 10-year survivors of breast cancer
Stroke rates and risk factors in patients treated with radiation therapy for early stage breast cancer
Inverse-planned, dynamic, multi-field, intensity modulated radiation therapy (IMRT) for left sided breast cancer: comparison to best standard technique
One year analysis of cosmesis and treatment efficacy by the American Society of Breast Surgeons (ASBS) MammoSite breast brachytherapy registry trial in patients treated with accelerated partial breast irradiation (APBI)
ATM sequence variants as predictors for adverse radiation responses in breast cancer patients
Improved survival, quality of life (QOL), and quality-adjusted survival (QAS) in breast cancer patients treated with efaproxiral (EFAPROXYN™)+whole brain radiation therapy (WBRT) for brain metastases
Radiation therapy and cardiac toxicity in breast cancer patients 65 years and older: a population-based study
Accelerated partial breast irradiation compared to whole breast radiotherapy: the potential for reduced contralateral breast dose and heart dose
A phase I dose escalation trial of gemcitabine with radiotherapy for breast cancer in the treatment of chest wall recurrences
Targeted intraoperative radiotherapy (TARGIT) as a boost yields very low recurrence rates
Breast magnetic resonance imaging (MRI) enhancement beyond the tumor margin: implications for radiation therapy
Risk of internal mammary recurrence after mastectomy in absence of internal mammary chain radiation therapy. A retrospective study
Frequency of asymptomatic brain metastases in Her-2 positive breast cancer patients
Over expression of apoptotic markers - p53 and bcl-xl is associated with axillary recurrence following radiotherapy in breast cancer patients
Improved survival after radiotherapy for brain metastases in patients with HER2 positive breast tumors
Efficacy of accelerated partial breast irradiation (APBI) as a neoadjuvant treatment for patients with breast cancer: a pilot study
Mammosite brachytherapy: predictive factors for complications and cosmesis
Fatty acid synthase (FAS)-catalyzed endogenous fatty acid metabolism regulates Her-2/neu (erbB-2) oncogene expression via malonyl-coenzyme-a-dependent expression of the Ets protein polyomavirus enhancer activator 3 (PEA3), a transcriptional repressor of Her-2/neu promoter activity in cancer cells
Epigenetic alteration of a protein tyrosine phosphatase and its role in tamoxifen-resistance in breast cancer
EPLIN, epithelial protein lost in neoplasm, is aberrantly expressed in human breast cancer and is related to clinical outcomes
BRCA1 promoter methylation confers sensitivity to cisplatin in vitro
ER status and age-at-diagnosis determine frequency and structural severity of breast cancer p53 mutations
The human p53 gene encodes nine p53 protein isoforms that can modulate p53 tumour suppressor activity
mda-7: a remedy for oncogene addiction in breast cancer?
Brg1, a chromatin remodeling gene, is suppressed in ER-negative breast cancer in human
Notch ligands and receptors are co-expressed at high levels in a subset of breast tumors with poor prognosis pathological features
Pattern of expression of genes linked to epigenetic silencing in human breast cancer
Genomic alterations in axillary lymph node metastases are associated with clinical outcomes in patients with breast cancer
Manipulation of expression of MMP-14 and its impact on the invasivess and progression of breast cancer cells
Osteopontin expression increases lymphatic metastasis of breast cancer: experimental and clinical studies
Withdrawn by Author
Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and proliferation
The CxCR4 mRNA and/or protein expression in breast cancer tissue does not always correlate with cancer metastasis
Targeting Rho-C by way of ribozyme transgene in human breast cancer cells and its impact on cancer invasion
The use of DNA microarray to determine potential pathways of tumor cell metastasis
The role of angiotensin II in integrin mediated breast cancer cell metastasis
Gene profile of fibroblasts from involved and uninvolved lymph nodes from breast cancer patients and influence of malignant cancer cells on their gene expression
Enhanced growth of KGF-transfected human breast cancer cells in a mouse xenograft model
Increased expression of CD44 in visceral metastases of breast cancer
Women with breast cancer heterozyous for CC chemokine receptor5Δ32 (Δ32/WT) may have a greater tendency for metastatic pleural effusion than those with wild type CCR5 (WT/WT)
Identification of estrogen regulated metastasis-associated genes using hormone-responsive bone metastases models
Expression of secretory leukocyte protease inhibitor in human breast carcinoma
Epidermal growth factor induces the IGF signaling protein insulin receptor substrate-2 via the JNK/AP-1 pathway and NF-kB transcription factor in breast cancer cells
Autophophorylation of the hepatocyte growth factor receptor, cMET in human breast cancer
Results of BCIRG 103: a presurgical study to evaluate molecular alterations that occur in human breast cancer tissue after short-term exposure to gefitinib
Gefitinib has a low clinical benefit rate in advanced breast cancer patients
Mammary specific overexpression of insulin receptor substrate-1 (IRS-1) or IRS-2 in mice results in tumorgenesis and metastasis
The ROCK Inhibitor Y-27632 supresses the effect of HGF in human breast cancer cells
Human epidermal growth factor receptor 1 (EGFR) expression was not associated with gene amplification but intimately associated with HER2 gene amplification and protein expression in tissue microarray of clinical breast cancers
Combination approach using RAD001 plus or minus tamoxifen or letrozole. A preclinical model of the treatment of endocrine-resistant breast tumours
The effect of silencing the insulin-like growth factor receptor on tamoxifen sensitive and tamoxifen resistant breast cancer cells
Does HER2 positive breast cancer have a prelediction to metastasise to the brain?
Inhibition of PCDGF/GP88 expression by SiRNA restores tamoxifen responsiveness in tamoxifen resistant breast cancer cells
The intrinsic effects of IGFBP-3 on the survival of human breast epithelial cells involve the sphingolipid 'rheostat'
EGFR is necessary but not sufficient for YB-1-mediated EGF independence
Estrogen receptor alpha modulates TGF-beta signaling independent from its activation status
Long term culture of MCF-7 breast cancer cells with small interfering RNA to the insulin-like growth factor receptor causes decreased cell proliferation
Blockade of p38 and JNK kinases inhibits the growth of normal and malignant breast cells
Anti-idiotype antibody vaccine therapy for HER2/Neu overexpressing breast cancer
Enhanced HER2/neu specific T-cell immunity in vitro by HER2/neu Ii-key modified "agonist" class II peptides in breast cancer patients
CpG DNA augments dendritic cell-based therapy of breast cancer
Cellular immunotherapy in late stage breast cancer patients with reactivated autologous memory T-cells derived from bone marrow
Whole cell autologous/allogeneic vaccine induces an immune response to specific antigens in breast cancer patients
Evaluation of foxp3 expression in sentinel nodes in breast cancer patients
Synthetic peptide vaccine candidates and their matching profile with the proteome
An important role for AIB1 phosphorylation in mediating growth factor signaling dependent estrogen agonist activity of tamoxifen in breast cancer cells
Gene expression changes during acquired resistance to letrozole; a preclinical model of post-menopausal breast cancer
Raloxifene effectively inhibits the growth of tamoxifen resistant T47D:A18/PKCα tumor
The phytoestrogen resveratrol acts opposite of estrogen to inhibit migration and differentially signal to the actin cytoskeleton of metastatic breast cancer cells
Comparison of effects of 4-hydroxy-tamoxifen and trilostane on oestrogen-regulated gene expression in MCF-7 cells: up-regulation of oestrogen receptor beta
Glyceollins (I-III), novel anti-estrogenic phytochemicals isolated from soy
Down regulation of p42/44 MAPK and pAKT in response to neo-adjuvant tamoxifen or anastrozole (IMPACT) in ER positive breast cancer
Macrophage colony-stimulating factor (CSF-1) overexpression leads to mammary tumorigenesis: induction of CSF-1 receptor, c-fms, by steroid hormones
Lipid profile and homocysteine levels in postmenopausal women with early breast cancer at low risk treated for two years with exemestane: follow-up results of a randomized, placebo-controlled study
Aromtase X HER-2/Neu double transgenic mice: effect of local estrogen on mammary development and carcinogenesis
Total body aromatization is strongly correlated to plasma leptin levels in postmenopausal breast cancer patients
Effects of aromatase inhibitors on human osteoblast cells: a possible androgenic bone protective effects induced by exemestane
Effect of nomegestrol acetate on aromatase activity in MCF-7aro breast cancer cells
Estradiol is an anti-aromatase agent in human breast cancer cells
MRI surveillance downstages invasive cancer (IC) to DCIS in women at high risk for hereditary breast cancer
Clinical guidelines for early detection of tumor response to neoadjuvant chemotherapy for breast cancer using contrast-enhanced MRI
Correlating breast cancer grade and hypoxia status with MRI features
Observer variability in dynamic contrast-enhanced MRI when used for prediction of response to neoadjuvant chemotherapy in primary breast cancer
Mammographic breast density as a predictor for local recurrence after breast conserving surgery and radiotherapy
Effect of 4-hydroxytamoxifen gel treatment on breast density and safety in premenopausal women
Baseline radiological staging in primary breast cancer: impact of an educational intervention on adherence to published guidelines
Discomfort and pain during mammography
Estrogen receptor alpha gene polymorphisms and mammographic density in postmenopausal women without hormonal therapy
Significant improvement in the diagnosis of breast lesion by means of real-time elastographie
Menstrual-cycle dependence of breast parenchyma elasticity determined by realtime sonoelastography: finding the optimal time for examination
Clinicopathological and radiological characteristics of screening ultrasound-detected breast cancers with negative mammography findings
Is ultrasound useful in the management of patients with ductal carcinoma in situ?
Preoperative FDG-PET/CT can change the tumour stage in locally advanced breast cancer
Evaluation of 18-FDG PET in initinal staging of the axilla in breast cancer
Cone beam breast CT - a feasibility study with surgical mastectomy specimens
A chart review of method of detection of contralateral breast cancers in two different age cohorts of patients
Local recurrence rates in screen detected breast cancers from 1996-1997
An analysis of breast cancer recurrences for screen detected and symptomatic breast cancers diagnosed in the West Midlands in 1996 and 1997
Mammographic breast density, dense area and breast area by phase in the menstrual cycle
Association of travel distance to mammography and breast cancer tumor size at diagnosis
Resource and service implications of a screening clinic for women at increased breast cancer risk from a family history
Diffuse optical spectroscopy: a novel laser-based approach for breast cancer diagnosis and screening in young women
Role of fine needle aspiration cytology as an adjunct to core biopsy in the diagnosis of screen-detected breast carcinoma
Molecular profiling of human breast cancer with serum mass spectrum data
A phase II, randomized, placebo-controlled trial of the safety and efficacy of dexmethylphenidate (d-MPH) as a treatment for fatigue and "chemobrain" in adult cancer patients
Anemia is a common and neglected complication of adjuvant chemotherapy for early stage breast cancer
Greater area under the hemoglobin change curve is associated with improved outcomes in breast cancer patients receiving epoetin alfa for chemotherapy-related anemia
Acute and delayed chemotherapy-induced nausea and vomiting and its impact on quality of life in patients with breast cancer in community practice settings
A randomised controlled trial to assess the efficacy of Maharishi Amrit Kalash - an ayurvedic herbal compound in ameliorating toxicity of cancer chemotherapy in women with breast cancer
First and subsequent cycle pegfilgrastim results in low rates of neutropenic events in patients receiving myelosuppressive chemotherapy
Synchronicity: evaluating darbepoetin alfa administered at 300 mcg every three weeks to treat chemotherapy-induced anemia in breast cancer patients
Darbepoetin alfa administered once every three weeks is effective for treating chemotherapy-induced anemia
Comparison of outcomes in patients receiving standard community care while enrolled on a nationwide registry with those enrolled in a prospective nationwide community-based clinical trial
Darbepoetin alfa administered once every three weeks either synchronously or asynchronously with every-three-week chemotherapy improves anemia in breast cancer patients
Cost-utility evaluation of adjuvant hormonal options in postmenopausal women with breast cancer: tamoxifen vs. anastrazole vs. tamoxifen then exemestane
Cost-effectiveness of switching to exemestane following two-to-three years of therapy with tamoxifen in postmenopausal women with primary breast cancer
Cost-effectiveness of adjuvant chemotherapy for node + breast cancer: modeling the downstream effects of adjuvant TAC vs FAC: docetaxel (T), adriamycin (A), cyclophosphamide (C) compared to 5-fluorouracil (F) A C
Economic evaluation of sequential capecitabine (X) and taxanes vs. the combinations in patients (pts) with advanced/metastatic breast cancer (MBC): a Mexican Oncology Study Group (MOSG) Trial
Clinical and cost-effectiveness implications of the adjuvant transtuzumab in HER2+ breast cancer trials
Cost-evaluation of second generation adjuvant chemotherapy options in breast cancer
Predictive value of health economic models: similarity in lifetime results using three-year versus five-year observations from the ATAC Trial
Physician-based active cost management of gynecological-oncological therapies reducing pharmaceutical costs by - 83.4% in two years without leaving standard of care
Cost-effectiveness of nanoparticle albumin-bound paclitaxel versus docetaxel in the treatment of metastatic breast cancer
Microarray-based comparative genomic hybridisation (aCGH) analysis of breast cancer patients receiving neoadjuvant chemotherapy: analysis of tumour subtypes and chemotherapy-related molecular genetic changes
Predictive gene signatures for response to neoadjuvant TAC-chemotherapy from expression profiling
Preoperative doxorubicin / cyclophosphamide followed by docetaxel (AC-Doc) versus dose-dense doxorubicin and docetaxel (Adoc) as preoperative treatment in operable breast cancer: first analysis of the event-free survival of the GeparDuo-Study
Operable breast cancer: preliminary results of a phase II, double blind, placebo controlled, randomized trial of preoperative chemotherapy +/− gefitinib with biomarkers evaluation
Prospective data of additional patients treated with neoadjuvant therapy with paclitaxel followed by FEC chemotherapy with trastuzumab in HER-2 positive operable breast cancer, and an update of initial study population
Pathological complete response with neoadjuvant docetaxel, carboplatin and trastuzumab in HER2-positive, locally advanced breast cancer on behalf of the GETN(A) Group
Prospective randomized comparison of neoadjuvant / primary systemic therapy (PST) with dose-dense sequential epirubicin (E)/ paclitaxel (P) chemotherapy versus standard dose therapy regimen in patients with breast cancer (bc), multicentre study of the AGO, Germany): subgroup analysis of inflammatory bc
Mature results from a randomized phase III trial of docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC)
Evaluation of the effect of neoadjuvant chemotherapy on tumour microvessel density (MVD), pericyte coverage index (PCI) & vascular endothelial growth factor (VEGF) in primary breast cancer
Frequent pathologic complete responses seen with neoadjuvant q4week carboplatin and weekly paclitaxel ± weekly trastuzumab in resectable and locally advanced breast cancer: a Brown University Oncology Group (BrUOG) Study
A phase II randomized study to compare the neoadjuvant administration of docetaxel and vinorelbine or docetaxel followed by adriamycin and cytoxan with all chemotherapy administered in a dose dense fashion to women with stage II and stage III breast cancer
High pathological complete remission rates with paclitaxel and carboplatin ± trastuzumab (TC±H) following dose dense doxorubicin and cyclophosphamide (AC) supported by GM-CSF in breast cancer-a phase II study
Semi-quantitative gene expression profiling for therapy prediction in a breast cancer neoadjuvant therapy study applying docetaxel/epirubicin/cyclophosphamide
Multicenter study of nonpegylated liposomal doxorubicin and docetaxel as neoadjuvant treatment in patients with stage II - III breast cancer
Dose-dense taxotere (T) and adriamycin/cyclophosphamide (AC) as neoadyuvant treatment in locally advanced breast cancer (LABC)
Neoadjuvant capecitabine chemoradiation (X-RT) for patients (pts) with locally advanced breast cancer (LABC) failing anthracycline-based neoadjuvant therapy: findings from a prospective phase II trial
The farnesyl transferase (FTase) inhibitor (FTI) tipifarnib inhibits FTase in vivo and enhances the efficacy of neoadjuvant dose-dense doxorubicin-cyclophosphamide (AC) in patients with locally advanced breast cancer (LABC)
Neoadjuvant dose dense chemotherapy (NDDC) with sequential doxorubicin/cyclophosphamide (AC) followed by taxane yields high pathologic complete response (pCR) rate in stage II/III breast cancer
Response to primary chemotherapy in breast carcinoma depends on histological tumor type: a study on 860 patients from one institution
Quality of life during three-weekly versus weekly neoadjuvant docetaxel: a randomised trial
The changes of histologic and biologic markers induced by neoadjuvant chemotherapy in locally advanced breast cancer
Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients: GEICAM 2002-03 Study
Dynamic infrared imaging - a real-time, non-invasive tool for monitoring tumor response to neoadjuvant therapy for breast cancer
Recurrence rates after dynamic contrast enhanced-magnetic resonance image guided planning for breast conserving surgery following neoadjuvant chemotherapy for breast cancer
Impact of pre-operative three different regimens on breast-conservation surgery (BCS) and pathological complete response rates (pCR) in locally advanced breast cancer (LABC) in Pakistani patients
Preliminary results of a phase II study of neoadjuvant treatment with docetaxel (T), doxorubicin (A) and capecitabine (X) in locally advanced or inflammatory breast cancer
Neoadjuvant chemotherapy for invasive lobular carcinomas of the breast: a poorer response rate but not a worse prognosis than invasive ductal carcinoma
Neoadjuvant, biweekly, dose-dense chemotherapy with epirubicin and cyclophoshamid followed by docetaxel in primary breast cancer
Neoadjuvant dose dense chemotherapy alternating gemcitabine (G) + docetaxel (D) and vinorelbine (V) + epirubicin (E) in locally advanced non inflammatory breast carcinoma (LABC): a phase II study
Sequential FEC100 and taxotere as a neoadjuvant treatment for operable breast cancer
Monitoring early treatment response of breast cancer to neoadjuvant chemotherapy using MR spectroscopy
Skeletal effect of exemestane in the Intergroup Exemestane Study (IES) - 2 year bone mineral density (BMD) and bone biomarker data
Withdrawn by author
Inhibition of steroid sulfatase by 667 COUMATE (STX64): a new treatment paradigm for breast cancer
Rosiglitazone sensitizes breast cancer cells to early apoptosis and synergizes with roscovitine to inhibit cellular proliferation
Molecular changes in response to pre-operative endocrine therapy
Synergistic interaction between recombinant human insulin-like growth factor-binding protein 3 (rhIGFBP-3) and letrozole in estrogen positive breast cancer
A role for aromatase inhibition in the treatment of estrogen receptor-α negative breast carcinoma
Inhibition of ERα and PI3K/Akt pathways improve sensitivity of long term estrogen deprived breast cancer cells to antiestrogens
Randomized pre-operative study of 750mg of fulvestrant and 20mg tamoxifen in premenopausal women with estrogen receptor-positive breast cancer
Regulation of aromatase expression in the breast by LRH-1: a new potential target for breast cancer therapy
Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients
A randomised, blinded, phase II study of tipifarnib (Zarnestra®) combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy
Changes in estrogen binding to ER during endocrine therapy measured by serial [F-18]-fluoroestradiol positron emission tomography (FES PET)
Modeling for cost-effective strategies in adjuvant hormonal therapy for postmenopausal women with breast cancer: upfront aromatase inhibitors vs sequential tamoxifen-aromatase inhibitors
Metabolism of the aromatase inhibitor drug letrozole by the human hepatic cytochrome P450 enzyme system
A phase I, open-label, non-randomized, dose-finding safety, tolerance, and pharmacokinetic study of TAS-108 administered orally in postmenopausal female patients with breast carcinoma following standard endocrine therapies
Similar time to response between fulvestrant and anastrozole: comparison from two phase III trials
Ovarian histopathology in premenopausal patients with breast cancer receiving gonadotropin-releasing hormone(GnRH) agonist and/or cytotoxic chemotherapy
Side effect profile of anastrozole compared with tamoxifen in Japanese women: findings from N-SAS BC03 Trial
Celecoxib anti-aromatase neoadjuvant (CAAN) Trial for locally advanced breast cancer
Female sexual dysfunction and changes in hormonal levels in patients with early breast cancer on anti-estrogen therapy
Primary hormone therapy in locally advanced breast cancer
Tipifarnib with tamoxifen as a rescue for tamoxifen acquired clinical resistance for metastatic ER and/or PgR positive breast cancer after releapse under tamoxifen. Preliminary results
Tolerance for adjuvant letrozole in daily practice
Aromatase inhibitors (AIs) are unlikely to improve overall survival in postmenopausal women with stage I breast cancer
Standardization of estrogen and progesterone receptor assay values
Inhibition of MAPK restores anti-estrogen response in vitro and ERα expression in breast tumors
Estrogen-induced suppression of gene expression: mechanisms of down-regulation
Loss of estrogen receptor (ER) expression in MCF-7 cells following long-term exposure to fulvestrant
Scaffold attachment factor B1 (SAFB1) - an estrogen receptor α corepressor
Thyroid hormone may induce breast cancer progression via interactions with the estrogen receptor
Day of surgery affects estrogen receptor test results in women with breast cancer
Role of estrogen receptor α and corepressors in estrogen-mediated repression of genes
High ERβ expression is associated with improved survival on tamoxifen in breast cancer
Loss of heterozygosity at 14q does not correlate with estrogen receptor β negative breast cancer
Expression of estrogen receptor β variant mRNA in primary breast cancer - a potential role in predicting hormonal responsiveness
Estrogen (E2)/anti-estrogen driven estrogen receptor (ER) transcription complex assembly in resistant human breast cancer cell lines
ER-α36, a novel variant of estrogen receptor-α, mediates membrane-initiated mitogenic estrogen signaling in ER-negative breast cancer cells
Differential overexpressions of EGFR, c-erbB-2, and IGF1R in histological types, nuclear grades, and hormone receptors status of breast carcinoma
Method of cooking and risk of breast cancer in the Philippines
A single gene biomarker identifies undifferentiated breast cancers associated with short duration of breastfeeding
Past exogenous hormone use and current endogenous sex hormone status in postmenopausal women in the EPIC-Norfolk population cohort
Antidepressants and breast cancer risk: casual link or no cause for concern?
Pilot study of changes in mammographic density in women treated with letrozole or placebo on NCIC CTG MA17
Influence of family history on breast cancer risk in women with biopsy-confirmed benign breast disease: results from the Nurses' Health study
Ultra-sensitive GC/Tandem mass spectrometry assay for estradiol measurements in post-menopausal women
Unilateral congenetial breast abnormalities and laterality of breast cancer
The relationship between serum cholesterol level and axillary lymph node statu in breast cancer patients
Association of manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer in males and females
Ductal carcinoma in situ and risk factors for breast cancer: can we target individuals for surveillance?
Morphological and immunohistochemical aspects of the breast tissue in postmenopausal women before and after hormone replacement therapy
Transfer of lipids to HDL in patients with breast cancer
Risk factors in breast cancer, a myth - an Indian experience
The effect of the oral contraceptive pill on prognosis and survival in women with breast cancer
Prediction of axillary sentinel node status: study of a large single institution series of breast cancer patients
Telomere DNA content and allelic imbalance predict disease-free survival and define field cancerization in histologically normal tissue adjacent to breast tumors
Validation of reference genes for relative real time PCR to study hormone-dependent gene expression in breast cancer biopsies
Molecular risk estimation and adjuvant chemotherapy in node-negative breast cancer patients - a status report of the prospective clinical trial NNBC 3-Europe
Repeatability and sources of uncertainty in relative real time PCR gene expression measurements in breast cancer biopsies
Identification of predictive biomarker panels by computational modeling of treatment responses in breast cancer patients
A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH) and interobserver variability
Improvements of breast cancer cure fractions in surveillance, epidemiology, and end results (SEER) estimated using CanSurv software
Factors predicting the axillary lymph node status in women with an ER-positive breast cancer are age-dependent
Lymph node ratio (LNR) is better survival predictor than conventional nodal categories: a surveillance, epidemiology, and end results (SEER) database analysis for node-positive breast cancer (BC)
Flourescence in situ hybridization (FISH) as the primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience
Newly established ELISA suitable for evaluation of HER2 antibodies in sera of patients with primary or advanced breast cancer, or benign or premalignant breast lesions
Automation of preanalytical components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification
Blood oxygenation level dependent (BOLD) contrast MRI for early evaluation of breast cancer chemotherapy
Multicenter, phase IV randomized study to assess efficacy of continuous versus alternate administration of pamidronate to breast cancer patients with symptomatic bone metastasis: GEICAM/2000-01 Trial
Accurate tumor response assessment in bone-only metastatic breast cancer by comprehensive imaging and by new response criteria
Efficacy and safety of systemic samarium 153 therapy in metastatic breast cancer patients with widespread bone metastases
Non-inferiority of oral ibandronate to intravenous zoledronic acid for reducing markers of bone turnover in metastatic breast cancer patients
Intravenous ibandronate 15-minute infusion followed by daily oral ibandronate for metastatic bone disease: bone marker data
Safety of oral ibandronate and intravenous zoledronic acid in breast cancer patients with metastatic bone disease
Fractures negatively affect survival in patients with bone metastases from breast cancer
Efficacy and safety of intravenous ibandronate 6mg infused over 15 minutes: results from a 2-year study of breast cancer patients with metastatic bone disease
Changes in tumor metabolism and local bone turnover in patients treated for bone-dominant metastatic breast cancer measured by fluorodeoxyglucose (FDG) and fluoride positron emission tomography (PET)
Lobular carcinoma in situ (LCIS). Discovery modalities, treatments and long term outcome. Analysis of 183 cases
Role of sentinel lymph node biopsy in screen detected ductal carcinoma in situ: analysis of 587 cases
Effects of letrozole and anastrozole on ductal carcinoma in situ (DCIS): results from a randomised trial
Changes in DCIS features and treatment over a 20-year period. Analysis of 2512 patients
LIBERATE Trial: a safety study of tibolone in breast cancer surgery patients - design and baseline data
Vaginal estrogens appear to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors
Menopausal hormone therapy after breast cancer - why are the results so different?
The effects of natural progesterone and medroxyprogesterone acetate on risk markers for breast cancer in the normal postmenopausal breast
Role of hormonal replacement therapy(HRT) on clinical characteristics tumors histo-pronostic factors and survival of patients with breast cancer
Tibolone and its metabolites inhibit invasion of human mammary carcinoma cells in vitro
Hormone replacement therapy in women with breast cancer. A survey of patient's attitudes
The sentinel lymph node biopsy in male breast cancer: the European Institute of Oncology experience
Selective inhibition of ADAM metalloproteases blocks Her-2 extracellular domain (ECD) cleavage and potentiates trastuzumab in blocking the growth of Her-2 overexpressing breast cancer cells
4-OHT gel demonstrates potent clinical antiestrogenic activity in the breast: implications for treating benign breast pain and reducing cancer risk
The effects of relaxation guided imagery on natural killer (NK) cell and cytokine IL-2 induced NK cytotoxicity in breast cancer patients
Decision criteria for adjuvant chemotherapy or hormonal therapy in node negative breast cancer: results of a french oncologist survey
Premature menopause following chemotherapy for early stage breast cancer: long-term results from IBCSG trials V and VI
The evaluation of the clinical effectiveness of telemedicine in breast cancer multidisciplinary decision making: TELEMAM, a cluster randomised trial
Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit?
The Toyota production system applied to breast cancer care
Correlation between preference for adjuvant therapy prior to surgery and actual choice of therapy
One year outcomes of an early identification and intervention model to reduce upper extremity morbidity related to breast cancer treatment
Longitudinal patterns of weight gain after breast cancer diagnosis: observations beyond the first year
Meta-analysis examining the efficacy of serotonin selective reuptake inhibitors in the treatment of women with hot flashes
Time to progression as a surrogate endpoint of clinical benefit in the taxanes and aromatase inhibitors decade: "El Álamo" project
The effect of a pilot exercise intervention on bone remodeling and body composition in breast cancer survivors
Acute and delayed nausea still a considerable problem in adjuvant breast cancer chemotherapy
Breast cancer and HIV
The impact of paclitaxel on menstrual function
Attitudes and management approaches of physicians who care for women with DCIS
When less is more? Follow up strategies for patients with breast cancer
The adherence of practice guidelines in the assessment of bone health in women with chemotherapy-induced amenorrhea
A prospective longitudinal study of the impact of adjuvant chemotherapy for breast cancer (BC) on older patients' functional status and quality of life
Overestimation of risk among women with DCIS: longitudinal results from a cohort study
Post-decision regret following breast reconstruction among women with breast cancer
Memory impairments with anastrozole versus tamoxifen therapy in women with early stage breast cancer
Distress in a nationwide cohort study of Danish women treated for locoregional invasive breast cancer. Prevalence and associations with histopathological variables, type of treatment and social relations
Pre-surgical screening for emotional distress and psychiatric co-morbidity among women with newly diagnosed early stage breast cancer
Oncology rehabilitation improves patient physical function and emotional health
Determinants of presentation delay in locally advanced breast cancer
The role of fatigue in mediating "chemo fog" in breast cancer patients
What do patients bring to the consultation? Professional and social support in breast cancer: the role of childhood abuse
Using interleukin-6 and hypothalamus-pituitary-adrenal (HPA) axis function as potential diagnostic markers in the assessment of depression in patients with advanced breast cancer
Using the Brief Symptom Inventory-18 to screen patients referred to high-breast cancer risk assessment clinic: patient factors associated with "caseness" before and after counseling
Pre-chemotherapy assessment of cognitive function using functional magnetic brain imaging in women with breast cancer
A quantitative study of tumor response and progression-free survival as surrogate endpoints for overall survival in first-line treatment of metastatic breast cancer
Chemotherapy and cardiotoxicity in older breast cancer patients: a polulation-based study
Effects of taxanes alone or in combination with anthracyclines on tumor response, progression-free survival and overall survival in first-line chemotherapy of patients with metastatic breast cancer: an analysis of 4,256 patients randomized in 12 trials
A phase III randomized trial of doxorubicin (A) and docetaxel (D) versus doxorubicin and paclitaxel (P) in metastatic breast cancer - preliminary results of the Erasme 3 study
Timing of initiation of adjuvant chemotherapy for early breast cancer does not influence disease-free survival. A Spanish Breast Cancer Research Group (GEICAM) analysis
A multicenter phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with locally advanced and metastatic breast cancer. Preliminary report
Pegylated liposomal doxorubicin in previously treated patients with metastatic breast cancer- a large multicenter phase II trial
Results of a phase II trial of combination therapy with oral capecitabine and weekly paclitaxel for metastatic breast cancer: preliminary results in taxane pretreated women
Phase II trial of gemcitabine plus carboplatin (plus trastuzumab in HER2+ patients) in metastatic breast cancer patients
The impact of educational attainment on initial doses of breast cancer adjuvant chemotherapy
CHAT - an open-label, randomized phase II study of trastuzumab plus docetaxel with or without capecitabine in patients with advanced and/or metastatic, HER2-positive breast cancer: second interim safety analysis
Who profits most from a guideline basedTreatment for advanced breast cancer?
Characterization of anti-fatty acid synthase expression in normal breast and breast cancer
DD-M111/hAG-2 is highly expressed in ductal and lobular breast cancer
Increased tartrate-resistant acid phosphatase (Trap) expression in breast cancer, patients' sera and cell lines
Withdrawn by Author
The loss of 14-3-3 sigma (σ) protein expression in invasive adenocarcinoma of the breast is associated with promoter hypermethylation and a more favorable clinical outcome
Growth regulation is altered in cancer-containing breasts
Tumour necrosis factor-a converting enzyme (TACE) promotes apoptosis in breast cancers by cleaving HER4
Inhibition of BRCC36 enhances apoptosis by disrupting BRCA1 phosphorylation in breast cancer cells exposed to ionizing radiation
Therapeutic potential of antisense Bcl-2 as a chemosensitizer for patients with breast cancer
Bystander activity of Ad-mda7: human MDA-7 protein kills breast cancer cells via an IL-20 receptor-dependent pathway
The tumour-suppressor function of breast myoepithelial cells is mediated in part through regulation of S100A9
Evidence that PI3K/Akt pathway is involved in the short non genomic autocrine loop between 17-β estradiol and aromatase activity
(18)F flurothymidine (FLT) for imaging of tumor cell proliferation; an in vitro-study for monitoring chemo-endocrine treatment in breast cancer cells
The role of the JNK signaling pathway in breast cancer cell lines
The selectivity of Ras signaling in tumor formation
Non-transformed basal (cytokeratin 5/14 postitive) breast cells migrate in matrigel by collective cell migration